Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GRK2 | P25098 | 1/20 | 0.41 |
| ▸ | GRK3 | P35626 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1499344 | 1.00 | TP53 (0.47) | TP53RXFP1SMN1; SMN2LMNARAB9A | |
| SCHEMBL1499595 | 0.94 | TP53 (0.47) | TP53RXFP1SMN1; SMN2LMNARAB9A | |
| SCHEMBL1499597 | 0.94 | TP53 (0.47) | TP53RXFP1SMN1; SMN2LMNARAB9A | |
| SCHEMBL1499338 | 0.93 | SMN1; SMN2 (0.46) | TP53RXFP1SMN1; SMN2LMNARAB9A | |
| SCHEMBL1499342 | 0.93 | SMN1; SMN2 (0.46) | TP53RXFP1SMN1; SMN2LMNARAB9A | |
| SCHEMBL29973395 | 0.93 | SMN1; SMN2 (0.46) | TP53RXFP1SMN1; SMN2LMNARAB9A | |
| SCHEMBL1499537 | 0.88 | NAMPT (0.40) | TP53RXFP1SMN1; SMN2LMNARAB9A | |
| SCHEMBL1499538 | 0.88 | NAMPT (0.40) | TP53RXFP1SMN1; SMN2LMNARAB9A | |
| SCHEMBL12766948 | 0.88 | NAMPT (0.40) | TP53RXFP1SMN1; SMN2LMNARAB9A | |
| SCHEMBL1499594 | 0.87 | KMT2A (0.48) | TP53RXFP1SMN1; SMN2LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604063-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) | 2013-12-10 | — | — | US | claimed |
| JP-2011509280-A | — | — | 2011-03-24 | — | — | JP | claimed |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-03-03 | — | — | US | claimed |
| EP-2235000-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2010-10-06 | — | — | EP | claimed |
| WO-2009087238-A9 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-02-25 | — | — | WO | claimed |
| WO-2009087238-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-07-16 | — | — | WO | claimed |
| EP-3536691-B1 | CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NAT RECH SCIENT (FR) | 2022-10-05 | — | — | EP | disclosed |
| US-10654813-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-05-19 | — | — | US | disclosed |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | ABIVAX (FR) | 2020-01-21 | — | — | US | disclosed |
| EP-3536691-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2019-09-11 | — | — | EP | disclosed |
| US-20190022037-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-01-24 | — | — | US | disclosed |
| US-10130595-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2018-11-20 | — | — | US | disclosed |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | ABIVAX (FR) | 2018-05-10 | — | — | US | disclosed |
| US-8604063-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) | 2013-12-10 | — | — | US | disclosed |
| WO-2012131656-A2 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIÉTÉ SPLICOS (FR) | 2012-10-04 | — | — | WO | disclosed |
| EP-2505198-A1 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | Société Splicos (FR) | 2012-10-03 | — | — | EP | disclosed |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-03-03 | — | — | US | disclosed |
| EP-2235000-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009087238-A9 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-02-25 | — | — | WO | disclosed |
| WO-2009087238-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10130595-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | RBM17, RBM22, SF3B1 | TP53 1912/4885RXFP1 3619/4885SMN1; SMN2 7/4885 |
| US-20190022037-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | RBM17, RBM22, PRPF40A | TP53 3059/4885RXFP1 3544/4885SMN1; SMN2 13/4885 |
| US-10654813-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | RBM17, RBM22, PRPF40A | TP53 3059/4885RXFP1 3544/4885SMN1; SMN2 13/4885 |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | TP53, TP53BP1, BCOR | TP53 1/4885RXFP1 3883/4885SMN1; SMN2 2920/4885 |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | TP53, TP53BP1, BCOR | TP53 1/4885RXFP1 3883/4885SMN1; SMN2 2920/4885 |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | RBM17, SF3B5, SF3B1 | TP53 3942/4885RXFP1 2144/4885SMN1; SMN2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.